Quality of Life in People with HIV at the End of Life: Preliminary Results from the Last Gift Observational Cohort Study.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
03 Oct 2024
Historique:
medline: 3 10 2024
pubmed: 3 10 2024
entrez: 3 10 2024
Statut: aheadofprint

Résumé

As people living with HIV (PWH) age, they face new challenges that can have a negative impact on their quality of life (QOL) and mental health. This study enrolled PWH at the end of life (EOL) who were actively engaged in cure-related research in Southern California, United States. EOL was defined as having a prognosis of six months or less to live. We examined the relationship between QOL, mental health, and research participation. Structured assessments were used to collect comprehensive data on QOL and mental health. From 2017 to 2023, 35 PWH in their final stages of life who were actively engaged in cure-related research were enrolled. Their median age was 62.7 years, and most were White or otherwise non-Hispanic/non-Latino (90.6%), and male (86.7%). Changes in QOL and the presence of neurologic and psychiatric conditions, with a focus on depression and anxiety, were the primary outcomes assessed in this study. Participants had stable QOL scores throughout the study. There was an inverse relationship between QOL and BDI scores, with higher mean QOL scores being associated with lower mean BDI scores (p < 0.001). QOL remained stable among PWH who participate in cure-related research at EOL. The inverse relationship between QOL and depressive symptoms suggests that participation in cure-related research may improve QOL or reduce depressive symptoms in this population. Future interventions should look into ways to improve the well-being of PWH at EOL through research and customized mental health interventions.

Sections du résumé

BACKGROUND BACKGROUND
As people living with HIV (PWH) age, they face new challenges that can have a negative impact on their quality of life (QOL) and mental health.
SETTING METHODS
This study enrolled PWH at the end of life (EOL) who were actively engaged in cure-related research in Southern California, United States. EOL was defined as having a prognosis of six months or less to live. We examined the relationship between QOL, mental health, and research participation.
METHODS METHODS
Structured assessments were used to collect comprehensive data on QOL and mental health.
RESULTS RESULTS
From 2017 to 2023, 35 PWH in their final stages of life who were actively engaged in cure-related research were enrolled. Their median age was 62.7 years, and most were White or otherwise non-Hispanic/non-Latino (90.6%), and male (86.7%). Changes in QOL and the presence of neurologic and psychiatric conditions, with a focus on depression and anxiety, were the primary outcomes assessed in this study. Participants had stable QOL scores throughout the study. There was an inverse relationship between QOL and BDI scores, with higher mean QOL scores being associated with lower mean BDI scores (p < 0.001).
CONCLUSION CONCLUSIONS
QOL remained stable among PWH who participate in cure-related research at EOL. The inverse relationship between QOL and depressive symptoms suggests that participation in cure-related research may improve QOL or reduce depressive symptoms in this population. Future interventions should look into ways to improve the well-being of PWH at EOL through research and customized mental health interventions.

Identifiants

pubmed: 39361015
doi: 10.1097/QAI.0000000000003536
pii: 00126334-990000000-00518
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest related to this work.

Auteurs

Brahm Coler (B)

School of Medicine, University of Washington, Seattle, WA, USA.

Gordon Honerkamp Smith (GH)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.

Anish K Arora (AK)

Canadian Institute of Health Research Strategy for Patient-Oriented Research Mentorship Chair in Innovative Clinical Trials, Montreal, QC, Canada.
Center for Outcome Research and Evaluation, Research Institute of the McGill University Health Center, Montreal, QC, CA.
Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, CA.

Adam Wells (A)

School of Medicine, University of Washington, Seattle, WA, USA.

Stephanie Solso (S)

AntiViral Research Center (AVRC), University of California San Diego (UCSD), San Diego, CA, USA.

Cheryl Dullano (C)

AntiViral Research Center (AVRC), University of California San Diego (UCSD), San Diego, CA, USA.

Susanna Concha-Garcia (S)

AntiViral Research Center (AVRC), University of California San Diego (UCSD), San Diego, CA, USA.
HIV Neurobehavioral Research Center, UCSD, San Diego, CA, USA.

Eddie Hill (E)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.

Patricia K Riggs (PK)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.

Anastasia Korolkova (A)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.

Robert Deiss (R)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.

Davey Smith (D)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.
AntiViral Research Center (AVRC), University of California San Diego (UCSD), San Diego, CA, USA.

Erin E Sundermann (EE)

Division of Psychiatry, Department of Medicine, University of California San Diego, San Diego, California, USA.

Sara Gianella (S)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.

Antoine Chaillon (A)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.

Karine Dubé (K)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, California, USA.

Classifications MeSH